2016 Fiscal Year Final Research Report
New method for diagnosis for colon cancers by using stem cell as a target
| Project/Area Number |
26670377
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | インビボイメージング / 幹細胞 / 大腸がん / EGFファミリー |
|---|
| Outline of Final Research Achievements |
Epiregulin (EPR) is a member of EGF family ligands and exert numerous cellular functions including stem cell stimulation. EPR is synthesized as a membrane-anchored protein (pro-EPR) and then proteolytically cleaved to yield a soluble form of EPR. While it is expressed at relatively low levels in most adult tissues, EPR is overexpressed in human colon, breast, and other cancers. We developed several anti-EPR monoclonal antibodies that specifically recognize human EPR, but not other EGF family ligands. Anti-EPR antibody is internalized into epiregulin expressing cancer cells. Using this system, we developed a mouse in vivo imaging system for epiregulin producing tumor. Our results suggest that anti-EPR antibodies represent valuable tools for medical imaging and for delivering agents for the treatment of cancers
|
| Free Research Field |
細胞生物学
|
